Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Moriah H. Nissan"'
Autor:
David B. Solit, Barry S. Taylor, Neal Rosen, Michael F. Berger, Taha Merghoub, Omar Abdel-Wahab, Agnes Viale, Shakuntala Tiwari, Alexander N. Shoushtari, Elena I. Gavrila, Hannah C. Wise, Wenhuo Hu, Yijun Gao, Zhan Yao, Abigail N. Poteshman, Clare A. Nimura, Moriah H. Nissan, Amber J. Kiliti, Alexis M. Jones, Alexander N. Gorelick, Sizhi P. Gao, Dong Xu, Ye Liu, Weiwei Han, Jianjiong Gao, Arijh Elzein, Matthew T. Chang, Brooke E. Sylvester, Aphrothiti J. Hanrahan
This supplementary data file contains 5 figures pertaining to the tumor distribution of MEK1 hotspot mutations, functional characterization of further MEK1/2 mutants with and without MEK or ERK inhibitor treatment, and the sequence paralogy alignment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81a3e6dd9941792421f2a33dbc53984c
https://doi.org/10.1158/0008-5472.22426042.v1
https://doi.org/10.1158/0008-5472.22426042.v1
Autor:
David B. Solit, Barry S. Taylor, Neal Rosen, Michael F. Berger, Taha Merghoub, Omar Abdel-Wahab, Agnes Viale, Shakuntala Tiwari, Alexander N. Shoushtari, Elena I. Gavrila, Hannah C. Wise, Wenhuo Hu, Yijun Gao, Zhan Yao, Abigail N. Poteshman, Clare A. Nimura, Moriah H. Nissan, Amber J. Kiliti, Alexis M. Jones, Alexander N. Gorelick, Sizhi P. Gao, Dong Xu, Ye Liu, Weiwei Han, Jianjiong Gao, Arijh Elzein, Matthew T. Chang, Brooke E. Sylvester, Aphrothiti J. Hanrahan
Despite significant advances in cancer precision medicine, a significant hurdle to its broader adoption remains the multitude of variants of unknown significance identified by clinical tumor sequencing and the lack of biologically validated methods t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fdd1967470582e983e089d010a26b8b
https://doi.org/10.1158/0008-5472.c.6512212.v1
https://doi.org/10.1158/0008-5472.c.6512212.v1
Autor:
David B. Solit, Neal Rosen, Michael F. Berger, Nikolaus Schultz, Barry S. Taylor, Rona Yaeger, Paul B. Chapman, Antoni Ribas, Taha Merghoub, Zhan Yao, Aphrothiti J. Hanrahan, Li Kong, Shakuntala Tiwari, Cailian Liu, Helen Won, Ricardo Ramirez, Alexis M. Jones, Christine A. Pratilas, Moriah H. Nissan
Supplementary Figures S1-S8. Levels of RAS-GTP in melanoma cell lines (S1); Changes in pERK and cyclin D1 levels as function of time in cells treated with the MEK inhibitor PD0325901 (S2); Sk-Mel-113 (NF1 null) melanoma cells are resistant to AKT inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fa01184a7e049a99c0f1035761f883e
https://doi.org/10.1158/0008-5472.22402383
https://doi.org/10.1158/0008-5472.22402383
Autor:
Alexis M. Jones, Aphrothiti J. Hanrahan, Moriah H. Nissan, Sebastien Monette, Ziyu Chen, Wenhuo Hu, Sandra Misale, Isabell Schulze, Naresh Vasani, Cailian Liu, Xia Yang, Mohsen Abu-Akeel, Elisa de Stanchina, Nikolaus Schultz, Michael F. Berger, Neal Rosen, Taha Merghoub, David B. Solit
Publikováno v:
Cancer Research. 83:2-2
Large scale clinical genomic sequencing efforts have revealed inactivating mutations in the RAS-GTPase Neurofibromin 1 (NF1) in a significant subset of melanomas. To date, immunotherapy and MAPK pathway-directed targeted therapies have been largely i
Autor:
Matthew T. Chang, Dong Xu, Taha Merghoub, Yijun Gao, Michael F. Berger, Clare A. Nimura, Wenhuo Hu, Arijh Elzein, Omar Abdel-Wahab, David B. Solit, Alexander N. Shoushtari, Jianjiong Gao, Ye Liu, Zhan Yao, Brooke E. Sylvester, Weiwei Han, Moriah H. Nissan, Sizhi P. Gao, Hannah C. Wise, Agnes Viale, Aphrothiti J. Hanrahan, Amber J. Kiliti, Barry S. Taylor, Shakuntala Tiwari, Neal Rosen, Alexis Jones, Alexander N. Gorelick, Elena I. Gavrila, Abigail N. Poteshman
Publikováno v:
Cancer Res
Despite significant advances in cancer precision medicine, a significant hurdle to its broader adoption remains the multitude of variants of unknown significance identified by clinical tumor sequencing and the lack of biologically validated methods t
Autor:
José Baselga, Feras M. Hantash, Tiffany A. Traina, Antonio M. P. Omuro, James J. Harding, Julia E. Rudolph, Margaret K. Callahan, Daniel C. Danila, Rona Yaeger, Alan L. Ho, Ederlinda Paraiso, Hongxin Zhang, Michael F. Berger, Ritika Kundra, Ahmet Zehir, Leonard B. Saltz, Ping Chi, Douglas A. Levine, Gregory J. Riely, Neerav Shukla, David M. Hyman, Moriah H. Nissan, Alexandra Snyder, Mrinal Gounder, Yelena Y. Janjigian, Maeve A. Lowery, Matthew D. Hellmann, Debyani Chakravarty, Tara Soumerai, Sarah Fierberg Phillips, Marc Ladanyi, Shrujal S. Baxi, Andrew Grupe, Thomas Kaley, Barry S. Taylor, Jiaojiao Wang, Martin H. Voss, Paul Sabbatini, David B. Solit, Dana Rathkopf, Alexander N. Shoushtari, Nikolaus Schultz, Gopa Iyer, Jianjiong Gao, Paul K. Paik, Michael A. Postow, Sarat Chandarlapaty, Matthew T. Chang
Publikováno v:
JCO Precision Oncology. :1-16
Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and e
Autor:
Moriah H. Nissan, Kinisha Gala, Linde A. Miles, Debyani Chakravarty, Paul Sabbatini, Shaleigh A. Smith, Hongxin Zhang, Aijaz Syed, Ahmet Zehir, Sarah P. Suehnholz, Ahmet Dogan, Julia E. Rudolph, Maria E. Arcila, Ritika Kundra, Yifu Yao, Jianjiong Gao, Nikolaus Schultz, Michael F. Berger, Marc Ladanyi, Ross L. Levine, Lindsay M. LaFave, David B. Solit
Publikováno v:
Cancer Research. 81:99-99
Genomic sequencing of tumors is a routine part of cancer patient care. To address the need for a comprehensive resource that annotates the oncogenic effects and clinical actionability of somatic alterations in cancer, we developed OncoKB, a precision
Autor:
Chad M. Vanderbilt, Paul Sabbatini, Hongxin Zhang, Debyani Chakravarty, Marc Ladanyi, Nikolaus Schultz, Ahmet Dogan, Ahmet Zehir, Maria E. Arcila, Sarah P. Suehnholz, Lindsay M. LaFave, Moriah H. Nissan, Ross L. Levine, Jing Su, Kinisha Gala, Jianjiong Gao, Ritika Kundra, David B. Solit, Michael F. Berger, Julia E. Rudolph
Publikováno v:
Cancer Research. 80:3208-3208
OncoKB is a precision oncology knowledge base that annotates the oncogenic effects and clinical actionability of somatic alterations in cancer. Initially focused on solid tumors, OncoKB was introduced in 2016 with >200 genes and almost 3000 somatic a
Autor:
Debyani Chakravarty, Mikhail Roshal, Maria E. Arcila, Jianjiong Gao, Ahmet Dogan, Wenbin Xiao, Kseniya Petrova-Drus, Michael F. Berger, Nikolaus Schultz, Caleb Ho, Scott E. Millman, Lindsay M. LaFave, Ryan Ptashkin, David B. Solit, Mariko Yabe, Ritika Kundra, Moriah H. Nissan, Hongxin Zhang, David A. Knorr, Linde A. Miles, Ahmet Zehir, Ross L. Levine, Sarah P. Suehnholz
Publikováno v:
Blood. 134:2148-2148
Background: Over 300 somatic molecular variants in hematologic diseases are either specified as diagnostic criteria in the World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues, recognized as potentially actio
Publikováno v:
Cancer Discovery. 3:719-721
Summary: Resistance to RAF inhibitors is generally accompanied by reactivation of extracellular signal-regulated kinase (ERK) signaling. SCH772984, a selective, ATP-competitive inhibitor of ERK1 and ERK2, is effective in BRAF-mutant models in which r